WO2018093096A3 - Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin - Google Patents

Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin Download PDF

Info

Publication number
WO2018093096A3
WO2018093096A3 PCT/KR2017/012703 KR2017012703W WO2018093096A3 WO 2018093096 A3 WO2018093096 A3 WO 2018093096A3 KR 2017012703 W KR2017012703 W KR 2017012703W WO 2018093096 A3 WO2018093096 A3 WO 2018093096A3
Authority
WO
WIPO (PCT)
Prior art keywords
losartan
rosuvastatin
complex preparation
amlodipine
active ingredients
Prior art date
Application number
PCT/KR2017/012703
Other languages
French (fr)
Other versions
WO2018093096A2 (en
Inventor
Hyuk Jun Cho
Sol Ee Lim
Ho Taek IM
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm. Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62146632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2018093096(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm. Co., Ltd. filed Critical Hanmi Pharm. Co., Ltd.
Priority to EA201991190A priority Critical patent/EA201991190A1/en
Priority to CR20190265A priority patent/CR20190265A/en
Priority to SG11201903132YA priority patent/SG11201903132YA/en
Priority to MX2019005230A priority patent/MX2019005230A/en
Publication of WO2018093096A2 publication Critical patent/WO2018093096A2/en
Publication of WO2018093096A3 publication Critical patent/WO2018093096A3/en
Priority to PH12019500779A priority patent/PH12019500779A1/en
Priority to ZA2019/02720A priority patent/ZA201902720B/en
Priority to CONC2019/0004796A priority patent/CO2019004796A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical complex preparation including amlodipine, losartan and rosuvastatin as active ingredients. The pharmaceutical complex preparation of the present invention including amlodipine, losartan and rosuvastatin as the active ingredients exhibits excellent dissolution characteristics of all the active ingredients, and also has improved preparation stability. Therefore, the complex preparation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has ensured quality stability even when stored for a long period of time.
PCT/KR2017/012703 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin WO2018093096A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA201991190A EA201991190A1 (en) 2016-11-15 2017-11-10 PHARMACEUTICAL COMPLEX PRODUCT CONTAINING AMLODIPINE, LOZARTAN AND ROSUVASTATIN
CR20190265A CR20190265A (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
SG11201903132YA SG11201903132YA (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
MX2019005230A MX2019005230A (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin.
PH12019500779A PH12019500779A1 (en) 2016-11-15 2019-04-11 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
ZA2019/02720A ZA201902720B (en) 2016-11-15 2019-04-30 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
CONC2019/0004796A CO2019004796A2 (en) 2016-11-15 2019-05-10 Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160152077 2016-11-15
KR10-2016-0152077 2016-11-15

Publications (2)

Publication Number Publication Date
WO2018093096A2 WO2018093096A2 (en) 2018-05-24
WO2018093096A3 true WO2018093096A3 (en) 2018-07-26

Family

ID=62146632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012703 WO2018093096A2 (en) 2016-11-15 2017-11-10 Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin

Country Status (11)

Country Link
CO (1) CO2019004796A2 (en)
CR (1) CR20190265A (en)
DO (1) DOP2019000092A (en)
EA (1) EA201991190A1 (en)
EC (1) ECSP19040732A (en)
MX (1) MX2019005230A (en)
NI (1) NI201900048A (en)
PH (1) PH12019500779A1 (en)
SG (1) SG11201903132YA (en)
WO (1) WO2018093096A2 (en)
ZA (1) ZA201902720B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20120105317A (en) * 2011-03-15 2012-09-25 보령제약 주식회사 A combined formulation with improved stability
KR20150067777A (en) * 2013-11-29 2015-06-19 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
US20150190399A1 (en) * 2012-07-23 2015-07-09 Landsteiner Scientific S.A. De C.V. New differential-release pharmaceutical composition containing three active principles
KR20160038734A (en) * 2014-09-30 2016-04-07 한미약품 주식회사 Solid Pharmaceutical Composition Comprising Amlodipine and Losartan

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029654A1 (en) * 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
KR20120105317A (en) * 2011-03-15 2012-09-25 보령제약 주식회사 A combined formulation with improved stability
US20150190399A1 (en) * 2012-07-23 2015-07-09 Landsteiner Scientific S.A. De C.V. New differential-release pharmaceutical composition containing three active principles
KR20150067777A (en) * 2013-11-29 2015-06-19 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
KR20160038734A (en) * 2014-09-30 2016-04-07 한미약품 주식회사 Solid Pharmaceutical Composition Comprising Amlodipine and Losartan

Also Published As

Publication number Publication date
PH12019500779A1 (en) 2019-07-29
CR20190265A (en) 2019-08-22
MX2019005230A (en) 2019-08-14
EA201991190A1 (en) 2019-10-31
NI201900048A (en) 2019-10-11
WO2018093096A2 (en) 2018-05-24
CO2019004796A2 (en) 2019-05-21
ECSP19040732A (en) 2019-07-31
ZA201902720B (en) 2020-08-26
DOP2019000092A (en) 2019-09-30
SG11201903132YA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
WO2016064082A3 (en) Novel aminoalkyl benzothiazepine derivative and use thereof
MX2016014320A (en) Extended release suspension compositions.
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016020320A8 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
WO2018084627A3 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
WO2017127835A3 (en) Aqueous formulations and methods of preparation and use thereof
MX2019012803A (en) New bicyclic pyrazole derivatives.
WO2016012418A3 (en) Deodorant preparations comprising polyquaternium-16 polymers
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
PH12019500808A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
WO2018093096A3 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
WO2017222819A3 (en) Solid state forms of ixazomib citrate
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
WO2017210527A8 (en) Autotaxin inhibitors
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2015154883A8 (en) Neosoraphens
WO2019125166A3 (en) Hyaluronic acid formulations
EP3840754A4 (en) Acid addition salts of apomorphine, pharmaceutical compositions containing the same, and methods of using the same
TH1901002872A (en) Pharmaceutical complex preparation containing amlodipine, losartan and rosuvastatin.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17871986

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17871986

Country of ref document: EP

Kind code of ref document: A2